Anti-Human PD-L1 Reference Antibody (Tagitanlimab, RUO) (HV974186)

Name: Anti-Human PD-L1 Reference Antibody (Tagitanlimab, RUO)
Brand: abinScience
SKU: HV974186
Price: 176 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер

HV974186

Описание

Tagitanlimab (HV974186) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Реактивность видов

Human

Применения

ELISA, Bioactivity: FCM, Functional assay, Research in vivo, WB

Хозяинский вид

Human

Клоональность

Monoclonal

Изотип

IgG1-kappa

Проверенные приложения

Цель

B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1

Уровень эндотоксинов

< 10 EU/mg

Чистота

>95% as determined by SDS-PAGE.

Очистка

Protein A/G purified from cell culture supernatant.

Номер доступа

Q9NZQ7

Форма

Liquid

Буфер хранения

0.01M PBS pH 7.4.

Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.

Информация об использовании продукта

Применение	Разбавление
WB	1:500-1:2000

Устойчивость и хранение

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Альтернативные названия

A-167, HBM-9167, KL-A1672417649-97-7

Фон

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443

2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410

3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417

4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419

5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298

6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077

7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201

Примечание

For research use only. Not suitable for clinical or therapeutic use.

Изображения

SDS-PAGE

SDS-PAGE for Research Grade Tagitanlimab.
Bioactivity

Detects recombinant PDL1 (Catalog No: HV974011) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-PDL1 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human PDL1 (Catalog No: HV974011)
Lane 2: Negative control